Twenty-four fragments (44%) were conjugated to additional functional molecules, such as radioisotopes or cytotoxins. These immunoconjugate candidates were all studied as anticancer agents ...

Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.